India, Oct. 30 -- Biotech startup Helex has raised $3.5 Mn (around INR 31 Cr) in its seed funding round led by pi Ventures, with participation from a host of investors, including Bluehill.VC, US-based SOSV, among others.
The startup will deploy the capital to accelerate pre-clinical development of its lead programme, as part of which it is developing a drug to cure patients suffering from Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Besides, the capital will also be used for advancement of Helex's proprietary kidney-tropic LNP (lipid nanoparticles) delivery system and its Epic-Cure 3D genome-based drug design platform, which goes in the detail of the disease and the cells in the human body to maximise gene editing accuracy and ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.